NASDAQ:ACRV · NASDAQ Global Market
+$0.05 today
Vol 0.26M · Avg 0.60M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Company filings are the primary source for understanding what changed inside Acrivon Therapeutics, Inc. Common Stock before the market fully reacts. Review recent ACRV disclosures alongside price history and peer context to identify new risks, accounting changes, strategic updates, capital allocation decisions, and operating details that may affect the intrinsic value case.
Price History
Dividend-adjusted closing price
Change
+37.60%
Period High
$3.01
Period Low
$1.23
Latest
$1.72
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$496.47M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$172.36M
Immunic, Inc.
NASDAQ:IMUX
$148.72M
Vaxart, Inc.
NASDAQ:VXRT
$125.60M
Biomea Fusion, Inc.
NASDAQ:BMEA
$73.18M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$64.53M
Cibus, Inc.
NASDAQ:CBUS
$62.32M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$56.25M
aTyr Pharma, Inc.
NASDAQ:ATYR
$52.66M
What is the latest ACRV filing?
The latest filing shown is 4 dated Jun 22, 2026.
How many recent filings does ACRV have?
Intrinsic Alpha currently shows 20 recent filings for ACRV.
Explore More
Continue the stock analysis
Jump to another research area for this company.